Fig. 2.

Summary of clinical interactions and pharmacokinetic changes investigating the perpetrator and victim potential of vericiguat. AUC area under the concentration–time curve, AUC_0–12,md AUC from time 0 to 12 h after multiple dose administration, AUC_(0–22) AUC from time 0 to 22 h, AUC_(0–24) AUC from time 0 to 24 h, AUC_(0–24),md AUC_0–24 after multiple-dose administration, AUC_τ,md AUC within the dosing interval after multiple dosing, CI confidence interval, C_max maximum concentration within a dosing interval, C_max,md C_max within a dosing interval after multiple dose administration, C_trough trough concentration within a dosing interval